Daiichi Sankyo (Ranbaxy Era) — Ethics Grade D

Daiichi Sankyo (Ranbaxy Era) receives an overall ethics grade of D (32/100) on CancelCo's corporate accountability database. Sector: Pharmaceuticals. Market cap: Large Cap.

Category scores

• labor: 58
• privacy: 80
• consumer: 20
• environment: 65
• humanRights: 55

Documented incidents (3)

• Adulterated Generic Drugs (high, 2013) — Ranbaxy, while owned by Daiichi Sankyo, pleaded guilty to felony charges relating to the manufacture and distribution of adulterated drugs from two manufacturing sites in India. The company admitted to failing to meet safety standards and falsifying data to meet FDA requirements.
• FDA Import Ban (high, 2014) — The FDA prohibited the import of drug products from an additional Ranbaxy facility in Toansa, India, after inspectors found significant violations of good manufacturing practices. This marked the fourth facility under the group to face such sanctions.
• Concealment of Fraud in Sale (medium, 2016) — Daiichi Sankyo won a major arbitration award against the former owners of Ranbaxy, claiming they concealed the extent of the FDA's investigation and internal fraud during the 2008 acquisition. The case highlighted widespread systemic corruption within the subsidiary's operations.

Documented good deeds

• Oncology Breakthroughs — Successfully developed and distributed Enhertu, a targeted therapy that significantly improves outcomes for breast cancer patients with specific mutations.

Ethical alternatives

• Takeda Pharmaceuticals — Lower record of manufacturing systematic fraud and higher transparency in R&D.